AstraZeneca (LON:AZN - Get Free Report)'s stock had its "buy" rating restated by investment analysts at Berenberg Bank in a report issued on Monday, Marketbeat.com reports. They currently have a £142 price objective on the biopharmaceutical company's stock. Berenberg Bank's price objective points to a potential upside of 16.51% from the stock's previous close.
Several other analysts also recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a £110 price target on shares of AstraZeneca in a research report on Wednesday, July 30th. Shore Capital reiterated a "buy" rating and issued a £135 price target on shares of AstraZeneca in a research report on Tuesday, July 29th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of £131.75.
Check Out Our Latest Analysis on AstraZeneca
AstraZeneca Stock Performance
AZN stock traded down GBX 22 on Monday, hitting £121.88. The company's stock had a trading volume of 1,229,672 shares, compared to its average volume of 9,961,337. The firm has a 50 day moving average of £110.29 and a two-hundred day moving average of £109.33. AstraZeneca has a 1 year low of GBX 9,573.51 and a 1 year high of £130.74. The stock has a market cap of £188.94 billion, a price-to-earnings ratio of 2,295.29, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83.
Insider Buying and Selling
In other AstraZeneca news, insider Aradhana Sarin sold 9,563 shares of the company's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total transaction of £1,100,892.56. Insiders own 0.15% of the company's stock.
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
